MedTrace Logo

Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial

NCT00751361 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2008-09-11

No results posted yet for this study

Summary

Purpose is to evaluate Rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative. Rheopheresis is a method of therapeutic apheresis using the methodology of double filtration plasmapheresis to treat microcirculatory disorders.

Conditions

  • Dry Age Related Macular Degeneration

Interventions

DEVICE

Rheopheresis / double filtration plasmapheresis

Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.

Sponsors & Collaborators

  • Apheresis Research Institute

    lead OTHER

Principal Investigators

  • Frank HJ Koch, Prof. Dr. · University of Frankfurt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-11-30
Primary Completion
2003-01-31
Completion
2003-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00751361 on ClinicalTrials.gov